Announces the Initiation of Phase I Clinical Trial of T-1201, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose …